TRX-711 is formulated with a proprietary micro-emulsion formulation of Cinacalcet for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on dialysis. SHPT has been the major cause of death for the patients with CKD and routine dialysis, which prevalence is particularly high in Asian population. Because of very poor oral absorption, the current marketed Cinacalcet product must be taken with a high-fat diet to increase its oral bioavailability, with unavoidable high fluctuation in blood drug levels and severe GI side effects such as nausea and vomiting. Poor patient compliance has become a major issue and requires urgent attention to resolve.
TRX-711 is designed to improve absorption while maintain steady oral bioavailability without food effect, and therefore overcome the poor compliance to the patients taking current market products. TRX-711 is now under full development into clinical evaluation.